Molecular Imaging Agents


Chart_Collage_160   Published June 2014  •  Catalog no. MJA399K  •  Price US $3,850



Driven by advances in molecular probe design and biomarker detection methodologies, new imaging agents that can improve visualization of pathologies and cellular processes are changing the practice of diagnostic medicine. The ability of this new generation of contrast agents to detect metabolic changes at the molecular level has significant potential for improving visualization and quality of care. Targetable and activatable imaging agents are gaining interest for a wide range of diagnostic applications that include cardiology, neurology and soft tissue tumor detection. The number of healthcare conditions that can be effectively imaged noninvasively is expanding as a result of these innovative detection technologies. Targeted and activatable imaging agents offer a unique capability to generate unambiguous images by exploiting specific molecular targets, pathways or cellular processes. This new wave of imaging agents signals a paradigm shift in which the reagents take on new importance.

Bar_GraphMolecular Imaging Agents Report Prospectus (Download PDF)

Blue document Molecular Imaging Agents Report Order Form (Download PDF)


Highlights

· Analyzes and assesses emerging imaging diagnostic candidates, their capabilities, benefits, limitations and potential

· Profiles development-stage imaging agents and examines their clinical status and commercial prospects

· Analyzes key industry alliances and partnerships by imaging modality, and examines the impact of next-generation imaging candidates on future imaging markets

· Profiles market participants, their development activity and business strategies

· Evaluates the impact of economic, technology, and regulatory factors on the development and commercialization of emerging imaging agents


Summary of Contents

Executive Summary

The Evolving Diagnostic Imaging Market

Imaging Agent Product Segments
Antibodies
Conjugated Radioisotopes
Metabolic Biomarkers
Optical Probes
Nanoparticles
Targeted Imaging Agents
Activatable Imaging Agents

Evolution in Imaging Agent Market
Segments

Disease Detection
Image-Guided Drug Delivery
Physiological Process Mapping
Therapeutic Screening
Treatment Assessment
Differential Diagnosis

Molecular Imaging Agents & Imaging Modalities

MRI
Optical Imaging
PET
SPECT
Ultrasound
Multimodal Imaging

Molecular Imaging Agent Categories

Affibodies
Antibody Fragments
Antibodies Targeting Immune Factors
mAbs
Chimeric mAbs
Nanoparticles
Peptides
Small Molecules

Molecular Imaging Agents in Healthcare – Clinical Applications

Apoptosis
Cardiology
Angiogenesis
Integrins
Adenosine Receptors

Vascular Endothelial Growth Factor Receptors
Immunology
Autoimmunity & Inflammation
Metabolic
Diabetes
Neurology
Amyloid Peptides
Peripheral Benzodiazepine Receptors
Dopamine Receptors
Metabotropic Glutamate Receptor (Subtype 1, Subtype 5)
Norepinephrine Transporter
P-glycoprotein Transporter
Serotonin Receptors
Serotonin Transporter
Cannabinoid Receptors
Oncology
Carinoembryonic Antigen
Folate Receptors
EGFR/HER1 Receptor
HER2 Receptor
Estrogen Receptor
Glucose Transporters
Gastrin-releasing Peptide Receptors
Gastrin/cholecystokinin Receptor
L-Type Amino Acid Transporter
Matrix Metalloproteinase
Melanocortin-1
Prostate-specific Membrane Antigen (PSMA)
Sigma Receptors
Somatostatin Receptors

Market Factors
Regulations
Manage Care
Alliance Activity
Evolving Modalities

Company Profiles